BioXcel Therapeutics (BTAI) Non-Current Debt (2022 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Non-Current Debt of $77.9 million for Q1 2026, down 22.08% year-over-year from $99.9 million in Q1 2025, and down 8.04% quarter-over-quarter from $84.7 million in Q4 2025.
BioXcel Therapeutics (BTAI) Non-Current Debt (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Non-Current Debt history runs 5 years deep, the most recent figure standing at $77.9 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 22.08% year-over-year to $77.9 million; the TTM figure through Mar 2026 stood at $77.9 million (down 22.08% YoY), while the FY2025 annual figure was $84.7 million, down 17.41% from the prior year.
- Non-Current Debt for Q1 2026 stood at $77.9 million, down from $84.7 million in the prior quarter.
- The five-year high for Non-Current Debt was $104.4 million in Q3 2024, with the low at $61.1 million in Q2 2022.
- The 5-year median for Non-Current Debt is $97.2 million (2023), against an average of $93.8 million.
- The sharpest annual moves came in 2023 and 2026: Non-Current Debt jumped 58.57% in 2023, then fell 22.08% in 2026.
- BioXcel Therapeutics' Non-Current Debt stood at $93.1 million in 2022, then gained by 8.11% to $100.6 million in 2023, then grew by 1.9% to $102.5 million in 2024, then declined by 17.41% to $84.7 million in 2025, then slipped by 8.04% to $77.9 million in 2026.
- Business Quant data shows BTAI's Non-Current Debt at $77.9 million in Q1 2026, $84.7 million in Q4 2025, and $92.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.45 Bn | 43.48 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.59 Bn | 39.94 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 32.51 Bn | 30.84 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.81 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.04 Bn | 19.38 Bn | 683.80 Mn | - |
| 6 | Viatris | 19.00 Bn | 18.11 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.99 Bn | 11.46 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 130.00 Mn |
| 10 | BioXcel Therapeutics | 24.72 Mn | 24.72 Mn | 160,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.86 Mn |
| Dec 31, 2025 | 84.66 Mn |
| Sep 30, 2025 | 92.30 Mn |
| Jun 30, 2025 | 97.47 Mn |
| Mar 31, 2025 | 99.92 Mn |
| Dec 31, 2024 | 102.51 Mn |
| Sep 30, 2024 | 104.44 Mn |
| Jun 30, 2024 | 103.01 Mn |
| Mar 31, 2024 | 101.63 Mn |
| Dec 31, 2023 | 100.60 Mn |
| Sep 30, 2023 | 99.09 Mn |
| Jun 30, 2023 | 96.85 Mn |
| Mar 31, 2023 | 95.06 Mn |
| Dec 31, 2022 | 93.05 Mn |
| Sep 30, 2022 | 91.70 Mn |
| Jun 30, 2022 | 61.08 Mn |